Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Average Target Price of $290.00 According to Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $300.11.

A number of equities research analysts recently commented on the stock. UBS Group assumed coverage on shares of Charles River Laboratories International in a report on Wednesday. They set a “buy” rating and a $357.00 price target for the company. Deutsche Bank Aktiengesellschaft raised their price target on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, September 25th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Finally, Mizuho raised their target price on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th.

Insiders Place Their Bets

In other news, Director James C. Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the sale, the director directly owned 31,596 shares in the company, valued at approximately $9,478,800. This trade represents a 51.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,039 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $294.12, for a total value of $599,710.68. Following the transaction, the executive vice president directly owned 4,807 shares in the company, valued at $1,413,834.84. This trade represents a 29.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 90,990 shares of company stock worth $25,731,388. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRL. QRG Capital Management Inc. lifted its position in shares of Charles River Laboratories International by 13.2% in the 2nd quarter. QRG Capital Management Inc. now owns 2,183 shares of the medical research company’s stock worth $495,000 after purchasing an additional 255 shares during the period. Tidal Investments LLC raised its stake in Charles River Laboratories International by 26.5% in the second quarter. Tidal Investments LLC now owns 6,371 shares of the medical research company’s stock worth $1,445,000 after buying an additional 1,334 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Charles River Laboratories International in the second quarter worth about $172,000. NewEdge Advisors LLC boosted its position in Charles River Laboratories International by 32.6% during the 2nd quarter. NewEdge Advisors LLC now owns 4,236 shares of the medical research company’s stock valued at $961,000 after acquiring an additional 1,041 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in Charles River Laboratories International by 959.9% during the 2nd quarter. Squarepoint Ops LLC now owns 13,863 shares of the medical research company’s stock valued at $3,144,000 after acquiring an additional 12,555 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Up 0.0%

Shares of CRL stock opened at $290.32 on Wednesday. The business has a 50-day moving average of $277.46 and a 200 day moving average of $217.99. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International has a 1-year low of $146.20 and a 1-year high of $303.30. The stock has a market capitalization of $13.86 billion, a PE ratio of -59.86, a P/E/G ratio of 2.70 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 11.42 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.